NEJM 25 September 2014 Vol 371 1189 This week we start with mepolizumab. Before we know it, we encounter losmapimod. Enough is enough. I think the World Health Organization should convene an extraordinary meeting of the International Nonproprietary Names Committee with the sole purpose of Stopping Silly Names. Medical practitioners are serious people and they […]
Richard Lehman’s journal review—29 September 2014